Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

1. To estimate the effects of multiple doses of PD 0332334 on the elimination of a single dose of metformin from the body
2. To estimate the effects of multiple doses of metformin on the elimination of a single dose of PD 0332334 from the body
3. To evaluate the safety and tolerability when PD 0332334 and metformin are administered at the same time.

Detailed Description:

Additional Study Purpose Details: To assess the pharmacokinetics of metformin and PD 0332334 with concurrent administration.

On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

• Drug: Metformin
  
  225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
  Other Name: imagabalin
• Drug: Metformin
  
  Single, oral, 500 mg of metformin immediate release
• Drug: PD 0332334
  
  500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
• Drug: PD 0332334
  
  Single, oral, 300 mg dose of PD 0332334 immediate release formulation

• Cohort 1
  
  This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
  Interventions:
  

  • Drug: Metformin
  • Drug: Metformin
• Cohort 2
  
  This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
  Interventions:
  

  • Drug: PD 0332334
  • Drug: PD 0332334

Inclusion Criteria:

• Nonsmokers
• Male or female adults

Exclusion Criteria:

• Current or history of significant medical illness
• Smokers
• Illicit drug use